Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Operating Expenses (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Operating Expenses for 11 consecutive years, with $121.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 18.48% to $121.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $508.7 million, a 14.1% decrease, with the full-year FY2025 number at $508.7 million, down 14.1% from a year prior.
  • Operating Expenses was $121.7 million for Q4 2025 at Intellia Therapeutics, down from $125.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $155.5 million in Q1 2022 to a low of $52.9 million in Q1 2021.
  • A 5-year average of $123.2 million and a median of $124.9 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 194.11% in 2022, then dropped 19.89% in 2023.
  • Intellia Therapeutics' Operating Expenses stood at $93.3 million in 2021, then surged by 32.58% to $123.7 million in 2022, then increased by 11.58% to $138.0 million in 2023, then increased by 8.22% to $149.3 million in 2024, then dropped by 18.48% to $121.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Operating Expenses are $121.7 million (Q4 2025), $125.3 million (Q3 2025), and $124.2 million (Q2 2025).